Latest Articles

Publication Date
IDEAYA Announces First-Patient-In for Phase 1 Clinical Trial Evaluating IDE161 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Endometrial Cancer - Yahoo Finance

IDEAYA Announces First-Patient-In for Phase 1 Clinical Trial Evaluating IDE161 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Endometrial Cancer Yahoo Finance

Published: Dec. 10, 2024, 11 a.m.
IDEAYA Announces First-Patient-In for Phase 1 Clinical Trial Evaluating IDE161 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Endometrial Cancer - PR Newswire

IDEAYA Announces First-Patient-In for Phase 1 Clinical Trial Evaluating IDE161 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Endometrial Cancer PR Newswire

Published: Dec. 10, 2024, 11 a.m.
Gaps Identified in EC Clinical Trial Enrollment - Physician's Weekly

Gaps Identified in EC Clinical Trial Enrollment Physician's Weekly

Published: Dec. 5, 2024, 3:09 p.m.
Ananda set for heightened industry interest as clinical trials advance - broker - Proactive Investors UK

Ananda set for heightened industry interest as clinical trials advance - broker Proactive Investors UK

Published: Nov. 22, 2024, 1 p.m.
Lisata Therapeutics CEO David Mazzo on Q3 results; updates on key clinical trials and partnerships - Proactive Investors UK

Lisata Therapeutics CEO David Mazzo on Q3 results; updates on key clinical trials and partnerships Proactive Investors UK

Published: Nov. 14, 2024, 4:39 p.m.
eFFECTOR Therapeutics to Collaborate with the Dana-Farber Cancer Institute on an Investigator-Sponsored Phase 2 Clinical Trial Evaluating Zotatifin as Combination Treatment in ER+ Endometrial Cancer and in Low Grade Serous Ovarian Cancer - GlobeNewswire

eFFECTOR Therapeutics to Collaborate with the Dana-Farber Cancer Institute on an Investigator-Sponsored Phase 2 Clinical Trial Evaluating Zotatifin as Combination Treatment in ER+ Endometrial Cancer and in Low Grade Serous …

Published: May 20, 2024, 7 a.m.
Rubraca sheds positive light for PARP inhibitors in endometrial cancer - Clinical Trials Arena

Rubraca sheds positive light for PARP inhibitors in endometrial cancer Clinical Trials Arena

Published: April 2, 2024, 7 a.m.
Israel's Gynica starts clinical trial for endometriosis cure - Reuters

Israel's Gynica starts clinical trial for endometriosis cure Reuters

Published: March 14, 2024, 7 a.m.
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!